COO
Cooper Companies (The)
$74.41
▲ 1.5%Updated Aug 7, 11:30 AM ET
COO at a glance — five pillars scored 0–100 from real filed financials.
Overall: Weak · 33/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▼ Down 5.6% over the last 12 months
Market Cap
$14.47B
P/E
61.97x
Forward P/E (est.)
88.53x
ROE
2.8%
Revenue Growth
6.1%
EPS Growth
-42.6%
Profit Margin
5.6%
FCF Yield
19.1%
Debt / Equity
0.3x
ROIC
5.0%
Interest Coverage
6.49x
Current Ratio
1.27x
Dividend Yield
0.0%
Implied Growth (rev. DCF)
5.8%
Rating Score
33/100
Cooper Companies (The) (COO) is a large-cap company in the Health Care Supplies industry, part of the Health Care sector of the S&P 500, with a market value around $14.47B.
In its latest reported year it generated about $4.09B in revenue and $374.90M in net profit.
Our model rates COO Weak (33/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (9 years of history).
The filed history looks like a business competitors struggle to attack: high and steady margins, revenue that grows through cycles, and strong returns on capital.
65.9% average over the last 3 years
±1.2 pts around 65.2% across 9 years
grew in 7 of the last 8 year-over-year periods
positive in 9 of 9 years
5.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what COO's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. COO trades near $74.41, above its 50-day average ($64.27) and 200-day average ($72.78). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 75 it is overbought — the recent rally is stretched and can cool off.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. COO's is $1.84 (~2.5% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month COO found buyers near $61.09 (support) and sellers near $74.45 (resistance); its 52-week range is $58.89–$89.83. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.8× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
4Y CAGR
8.8%
Revenue moved from $2.14B in 2017 to $4.09B in 2025, a 8.4% compound annual growth rate. The most recent year grew a steady 6.1% year over year. Slower, mature growth is common for established businesses.
Gross Margin
65.5%
Operating Margin
16.7%
Net Margin
9.2%
ROE
2.8%
Cooper Companies (The) keeps about 5.6% of each sales dollar as net profit, with a 65.5% gross margin and 16.7% operating margin. Return on equity is 2.8% and return on invested capital about 5.0%. Margins are moderate — typical of a competitive but profitable business.
Total Debt
$2.26B
Net Debt
$2.12B
Net Debt / EBITDA
3.11x
Debt / Equity
0.3x
Leverage: debt-to-equity is 0.3x, and operating profit covers interest about 6.5x, with a current ratio of 1.3x. That is a conservative balance sheet — a cushion in downturns. It carries roughly $2.26B of total debt against $138.80M of cash.
Operating CF
$796.10M
Free Cash Flow
$433.70M
FCF Margin
10.6%
In the latest year Cooper Companies (The) produced about $796.10M of operating cash flow and $433.70M of free cash flow after capital spending. That is a free-cash-flow yield of about 19.1% on today's price. Strong cash generation funds dividends, buybacks, and reinvestment.
Can the payout survive a bad year? Scored from filed cash flow, earnings coverage, and the raise/cut record.
The payout is comfortably covered by cash the business actually generates, with a raise habit behind it.
Dividend yield
0.0%
Per share (latest FY)
$0.03
Total paid (latest FY)
$3.00M
History on record
7 years
dividend uses 1% of free cash flow
1% of net income paid out
no current raise streak
no cuts in the last 7 years on record
Coverage uses the latest fiscal year as filed with the SEC; the streak counts total dollars paid (per-share figures can carry split artifacts). Educational information, not income advice.
P/E
61.97x
P/S
3.23x
P/B
1.86x
EV / EBITDA
—
COO trades at 62.0x trailing earnings (about 88.5x on estimated forward earnings), 3.2x sales, and 1.9x book value. Reverse-engineering today's price implies the market expects roughly 5.8% long-term free-cash-flow growth. That is a rich multiple that prices in a lot of future growth.
A two-stage discounted cash flow on real SEC-filed free cash flow — the intrinsic-value anchor professional analysts triangulate from.
DCF fair value / share
$42.96
Current price
$74.41
Starting FCF (latest 10-K)
$433.70M
Growth, years 1–5
6.1%
Fade to terminal, years 6–10
2.5%
Discount rate
9.0%
Cash flows grow at the stage-1 rate (trailing revenue growth, capped at 20%) for five years, fade to 2.5% by year 10, and continue at that rate forever (Gordon terminal value), all discounted at 9.0%. Small changes in assumptions move the result a lot — treat this as one reference point, not a target price. Educational only, not investment advice.
Where COO sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How COO stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), COO ranks #70 of 324 by our overall rating. It trades at a premium versus the sector on earnings (62x P/E vs. 27.3x median) with a lower return on equity (2.8% vs. 14.1%) and slower revenue growth (6.1% vs. 7.6%).
P/E vs sector
62x
median 27.3x
ROE vs sector
2.8%
median 14.1%
Growth vs sector
6.1%
median 7.6%
Sector rank
#70
of 324 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $74.41 today · expected CAGR 5% – 16%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $4.34B | $4.60B | $4.87B | $5.17B | $5.48B |
| Net income | $390.41M | $413.84M | $438.67M | $464.99M | $492.89M |
| EPS | $2.01 | $2.13 | $2.26 | $2.39 | $2.53 |
| Share price (low) | $74.28 | $78.73 | $83.46 | $88.46 | $93.77 |
| Share price (high) | $124.46 | $131.93 | $139.85 | $148.24 | $157.13 |
| CAGR (low–high) | -0% / 67% | 3% / 33% | 4% / 23% | 4% / 19% | 5% / 16% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for COO:
- Healthy free-cash-flow yield (~19.1%) funds buybacks and dividends.
- A conservative balance sheet (debt/equity 0.3x) lowers risk.
The case against COO:
- A rich 62.0x earnings multiple prices in a lot of growth.
- Our model's overall read is Weak (33/100).
Valuation risk — at 62.0x earnings, disappointing results could compress the multiple.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen weakly: Cooper Companies (The) is a large-cap health care business growing at a mature pace, with modest profitability, and a sound balance sheet. It trades at 62.0x earnings, which our model scores Weak (33/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 23 Wall Street analysts covering COO recommend (August 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
COO's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
In the Idea Lab
COO — frequently asked questions
Is COO a good stock to buy?
We don't give buy or sell advice. Our model rates Cooper Companies (The) Weak (33/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is COO's rating on The Stocks School?
Cooper Companies (The) currently scores 33/100 (Weak) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does COO's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Cooper Companies (The)'s SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for COO calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this COO analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell COO. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.